Skip to Content

Inogen names new CEO

Inogen names new CEO Retiring CEO Scott Wilkinson has agreed to provide transition services as a non-executive employee until June 4

GOLETA, Calif. – Inogen’s board of directors has appointed Nabil Shabshab as president and CEO effective Feb. 8. 

Shabshab will replace Scott Wilkinson, who announced that he would be retiring in June last year. 

Shabshab will also serve as a Class II director, with a term expiring at the annual stockholders meeting in 2022. 

Shabshab, 56, has most recently served as worldwide president of diabetes care and digital health at Becton Dickinson and Co., since August 2017. Previously, he served as the company’s chief marketing officer and executive vice president of strategic planning. He’s also worked at Diversey, The Zyman Group, Symphony IRI, Waner Lambert/Pfizer, the Coca-Cola Co. and Fronterra. 

Shabshab’s employment agreement provides for an annual base salary of $650,000, a target annual bonus opportunity of 85% of his base salary and a cash sign-on bonus of $1.7 million, according to a Form 8-K filed with the Securities and Exchange Commission. 

The agreement also provides for an equity award of restricted stock units (RSUs) covering shares of Inogen’s common stock, with an initial value of about $1.8 million; and for an equity award covering shares of the company’s common stock, with an initial value of about $2 million, according to the form. 

Wilkinson has agreed to provide transition services to Inogen as a non-executive employee until, at the latest, June 4, 2021. He will continue to receive his current base salary and other benefits, according to the form. 


To comment on this post, please log in to your account or set up an account now.